The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Adding preoperative chemoradiotherapy to perioperative chemotherapy failed to boost survival, versus perioperative ...

Tailored dose-dense adjuvant chemotherapy improved long-term outcomes over standard adjuvant chemotherapy in patients with high-risk early breast cancer.

Zydus Lifesciences is one of the biggest names in the pharma business of the country. In a recent development, the company ...

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...

Perioperative pembrolizumab can improve OS when combined with neoadjuvant chemotherapy in patients with high risk, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

Sterling Biotech is one of the large manufacturers of pharmaceutical gelatin, di-calcium phosphate and APIs including ...

Zydus Lifesciences Ltd on Tuesday said it will acquire the 'Target Business' of Sterling Biotech primarily engaged in ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Zydus Lifesciences has acquired Sterling Biotech's API business, including a fermentation-based API production facility, for ...